Table 5.
Biomarkers (glypican-1-positive circulating exosomes and carbohydrate antigen 19-9) profiles in the study groups, n = 88
Biomarker
|
MCL, n = 40
|
HR, n = 20
|
NLOD, n = 20
|
CG, n = 8
|
Total, n = 88
|
P
value
|
GPC1+ crExos, % | < 0.001 | |||||
Median | 99.4 | 82.0 | 12.6 | 16.2 | 86.8 | |
Min/Max | 6.4/99.9 | 1.1/99.0 | 2.1/93.9 | 1.2/24.5 | 1.1/99.9 | |
IQR | 94.9-99.8 | 28.9-98.2 | 5.2-63.4 | 6.6-20.1 | 18.6-99.4 | |
CA 19-9 in U/mL | NS | |||||
Median | 20.4 | 16.9 | 18.8 | 30.6 | 18.4 | |
Min/Max | 8.5/206.6 | 8.3/28.0 | 12.8-48.7 | 13.7-69.6 | 8.3/206.6 | |
IQR | 14.0-35.8 | 11.7-18.1 | 16.6-23.4 | 15.0-40.8 | 14.2-27.7 |
P value for Kruskal-Wallis test. CA 19-9: Carbohydrate antigen 19-9; CG: Control group; HR: Hereditary risk; IQR: Interquartile range; GPC1+ crExos: Glypican-1 positive circulating exosomes; Max: Maximum; MCL: Mucinous cystic lesion; Min: Minimum; NLOD: New-late onset diabetes mellitus; NS: Non-significant.